SYNTEKABIO, INC.
KKRX:2263301,069.00
KRW
+56.00
(+5.53%)
SYNTEKABIO, INC.
KRX:226330
(Korea Stock Exchange)
Recent
price
1,069.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.- Similar Companies
- Business
- Syntekabio, Inc. is a South Korea-based biotechnology and bioinformatics company specializing in artificial intelligence (AI)-driven drug discovery and genomic big data analytics. Founded in 2009 and headquartered in Daejeon, South Korea, the company operates within the life sciences and healthcare technology sectors, serving global pharmaceutical corporations, biotechnology enterprises, academic institutions, and clinical research organizations. Syntekabio maintains an international footprint supported by its overseas subsidiary, Syntekabio USA Inc., located in New York, United States. The company combines deep learning algorithms, structural biology, and high-performance computing infrastructure to accelerate early-stage target identification, hit generation, and lead optimization for synthetic chemical drugs and biologics. The company provides a comprehensive suite of proprietary AI platforms, SaaS solutions, and preclinical research services, including: DeepMatcher, an AI-powered small-molecule drug discovery platform for virtual high-throughput screening and molecular dynamics simulations to optimize lead compounds; LM-VS (Language Model-Based Virtual Screening), a cloud-accessible hit-discovery engine utilizing inverted indexing algorithms to evaluate billions of chemical structures against target proteins; STB CLOUD, a software-as-a-service delivery platform providing on-demand access to proprietary drug design tools without requiring local computational hardware; NEO-ARS, an AI-driven neoantigen prediction platform for the design of personalized and universal cancer immunotherapies; Ab-ARS, an antibody optimization and de novo design platform predicting complementarity-determining regions for biotherapeutic development; NGS-ARS, a next-generation sequencing genomic analysis system for precision oncology, biomarker discovery, and rare genetic disease profiling; the AI Bio-Supercom Center (ABSC), a dedicated high-performance supercomputing infrastructure facility supporting complex computational biology workflows; and custom drug development services offered through flexible commercial arrangements, including the Develop Now, Pay Later program and the proprietary AI Asset Program. In recent operational and strategic developments, Syntekabio has accelerated the commercialization of its AI discovery engines and expanded its computational business operations. The company transitioned its AI Asset Program into the assetization phase to commercialize and license internally developed therapeutic assets. In biotherapeutic partnerships, Syntekabio executed an out-licensing agreement with Panolos Bioscience for five AI-designed multispecific antibody candidates and established a multi-billion KRW preclinical research collaboration with U.S.-based Pragma Bio to discover drug targets for inflammatory bowel disease. The company entered into a strategic collaboration with global chemical supplier Enamine to integrate millions of synthetic screening compounds directly into the DeepMatcher platform. Additionally, Syntekabio advanced its collaborative chronic obstructive pulmonary disease program with Australia-based QIMR Berghofer Medical Research Institute, secured a service integration agreement with the Weverse unit of HYBE, and formally expanded its corporate business scope to offer commercial B2B high-performance data center colocation, leasing, and consulting services utilizing its AI Bio-Supercom Center facility.